Harmony Biosciences Holdings Inc — Financial Statements (NASDAQ:HRMY) | MetaTrader

Open full chart

Nouvelles

BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y

IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress

RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up

Corcept's Q4 Earnings and Revenues Fall Short of Estimates

Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y

Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y

UBS réduit l’objectif de cours d’Harmony Biosciences suite à une entrée anticipée des génériques de Wakix

UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry

Needham maintient son achat sur Harmony Biosciences Hldgs, mais abaisse l'objectif de cours à 44 $. | Benzinga France

Truist maintient sa recommandation Conserver sur Harmony Biosciences, objectif à 25$

Truist reiterates Hold on Harmony Biosciences stock, sets $25 target

AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales